Name: Otsuka Pharmaceutical Development & Commercialization, Inc.
Address: 508 Carnegie Ctr Ste 100, Princeton, NJ, 08540-6395, USA
Telephone: (609) 524-6788

Welcome to Otsuka America Pharmaceutical, Inc.

Established in 1989, Otsuka America Pharmaceutical, Inc. (OAPI) is the part of the Otsuka Group (Otsuka) that oversees all pharmaceutical and medical device commercial activities in North America.

With an emphasis on neuroscience, oncology, cardio-renal, and medical device markets, OAPI has a proven record of successfully commercializing Otsuka-developed and in-licensed products, including products from Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). To learn more about OAPI's marketed products, click here.

We are not the largest company in the industry, but our goal is to be the most highly regarded. We want to be known for bringing the best value possible to our customers through our clinical expertise, market knowledge, and understanding of clinical practice. To that end, we seek to be a magnet for talent, a place where the best employees choose to further their careers.

OAPI transforms the ability of our workforce to communicate more effectively through technology and helps each individual achieve higher aspirations through personal development. Structured to empower our people with the freedom to discover new and better ways to serve the healthcare community, we are poised to continue the amazing growth OAPI has experienced in recent years through new product launches and additional alliances.

Otsuka America Pharmaceutical, Inc. (OAPI) is a growing healthcare company, with a strong focus and commitment to neuroscience, oncology and hospital therapies. OAPI is responsible for all pharmaceutical and medical device commercial activities in North America and is part of the Otsuka Group which is comprised of 153 companies and employs 36, 000 employees worldwide in 23 nations and regions throughout the world. OAPI has corporate offices in Rockville, Maryland and Princeton, New Jersey and employs over 500 pharmaceutical industry professionals. OAPI is supported by a network of Otsuka research institutes around the world that focus on pioneering and developing new treatments and indications. OAPI has built a solid business foundation on Otsuka-developed products and continues to build on this foundation to achieve its corporate vision: A strong and highly competitive organization capable of successfully launching our own products for better patient outcomes. In 2009, OAPI is taking on greater responsibility for driving the growth of ABILIFY(R) (aripiprazole) in the US by building a strong neuroscience organization to maximize growth within the psychiatric community. OAPI is also focused on growing its oncology, hospital, and device businesses. Current Product Portfolio ABILIFY(R) (aripiprazole) Tablets, approved November 2002. Please see FULL PRESCRIBING INFORMATION including Boxed WARNINGS for ABILIFY. SAMSCATM (tolvaptan), approved May 2009. Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for SAMSCA. IV BUSULFEX(R) (busulfan) Injection, acquired March 2008. Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for IV BUSULFEX. BreathTekTM Urea Breath Test (UBT) for H.pylori Kits, acquired September 2007. Please see FULL PRESCRIBING INFORMATION for BreathTek. PLETAL(R) (cilostazol) Tablets, approved January 1999. Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for PLETAL.
Annual Sales Since 2004, our annual net sales have grown by 300%, with 2008 net sales exceeding $2.6 billion.

Otsuka Pharmaceutical Development & Commercialization, Inc.

Business Info

Contact Business

Company Summary

Similar Businesses Nearby

Competitive Landscape

Payments Accepted

Hours

Photos

Business Credit Report

Facebook

Twitter

Yelp

Customer Resources

Our Company

Our Network

Site Links